Absence of Glutathione S-Transferase Theta 1 Gene is Significantly Associated with Breast Cancer Susceptibility in Pakistani Population and Poor Overall Survival in Breast Cancer Patients: A Case-Control and Case Series Analysis
Sadia AjaziD, Sani-e-Zehra ZaidiiD, Saleema Mehboob Ali, Aisha SiddiqaiD, Muhammad Ali MemoniD, Sadaf Firasat, Aiysha AbidiD, Shagufta KhaliqiD
Abstract
PurposeDeletion of Glutathione S-Transferase Theta 1 (GSTT1) encoding gene is implicated in breast cancer susceptibility, clinical outcomes, and survival. Contradictory results have been reported in different studies. The present investigation evaluated GSTT1-absent genotype for its contribution to breast cancer risk in Pakistani population and specific clinical outcomes in breast tumours. MethodsA prospective study comprising case-control analysis and case series analysis components was designed. Peripheral blood samples were collected from enrolled participants. After DNA extraction, GSTT1 genotyping was carried out by a multiplex PCR with {beta}-globin as an amplification control. Association evaluation of GSTT1 genotypes with breast cancer risk, specific tumour characteristics, and survival was the primary endpoint. ResultsA total of 264 participants were enrolled in the molecular investigation (3 institutions). The study included 121 primary breast cancer patients as cases and 143 age-matched female subject, with no history of any cancer, as controls. A significant genetic association between GSTT1-absent genotype and breast cancer susceptibility (p-value: 0.003; OR: 2.13; 95% CI: 1.08-4.29) is reported. The case-series analysis showed lack of association of GSTT1 genotypes with tumour stage (p-value: 0.12), grade (p-value: 0.32), and size (p-value: 0.07). The survival analysis revealed that GSTT1-absent genotype cases had a statistically significant shorter overall survival (OS) than those with GSTT1-present genotype cases (mean OS: 23 months vs 33 months). The HR (95% CI) for OS in patients carrying GSTT1-absent genotype was 8.13 (2.91-22.96) when compared with GSTT1-present genotype. ConclusionsThe present study is the first report of an independent, population-oriented significant genetic association between GSTT1-absent genotype and breast cancer susceptibility as well as OS in breast cancer cases. Upon further validation, GSTT1 variation may serve as a marker for devising better and population-specific strategies for screening and treatment in breast cancer management.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- FWCI
- 0.16
- Field percentile
- 41th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Germline Mutation Analysis in Sporadic Breast Cancer Cases with Clinical Correlations
Sadia Ajaz, Sani-e-Zehra Zaidi, … Muhammad Ali Memon·Frontiers in GeneticsPeer-reviewed·Mar 9, 2022
- The glutathione S-transferase Gstt1 is a robust driver of survival and dissemination in metastases
C. M. Ferrer, R. Boon, … R. Mostoslavsky·bioRxiv·Sep 10, 2022
- Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendations
Clare Turnbull, Maria Isabel Achatz, … William David Foulkes·medRxiv·Feb 25, 2025
- Association between polygenic risk and survival in breast cancer patients
Danielle E. Kurant, Stefan Groha, … Alexander Sasha Gusev·BMC CancerPeer-reviewed·Aug 28, 2025
- Glucocorticoid receptor gene polymorhisms and breast cancer: significant association in cancerous tissue samples from Turkish patients
Gürkan Akyildiz, Mustafa Akkіprіk, … Cenk Aral·bioRxiv·Mar 31, 2018
- GSTT1 mediates stemness and FGFR inhibitor sensitivity in pancreatic cancer through regulation of CD133 (PROM1)
Deborah de la Caridad Delgado Herrera, Alejandro Arroyo Roman, … Christina M. Ferrer·bioRxiv·Aug 6, 2025